Peer Review: Rubius recruits BD chief; Epizyme hires Novartis vet as CFO
→ Rubius Therapeutics — clinical-stage biopharmaceutical company developing a new class of medicines called red cell therapeutics — made the addition of Kris Elverum to its senior leadership team as SVP of business development and strategy. Elverum joins the company from Turnstone Biologics and has previously served at SQZ Biotech, Novartis and McKinsey & Co.
→ As Epizyme preps a transition to the commercial stage — which could come as early as next January if the FDA comes through — it’s installing Paolo Tombesi as CFO. A Novartis vet, Tombesi has overseen a similar transition for Insmed, helping launch a subsidiary in Japan and bringing in more than $1 billion by Epizyme’s count. Aside for the sarcoma application, now under priority preview, a second NDA for tazemetostat is slated for later this year, he added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.